Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Breast and Gynecologic Cancers Research Group / FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

OVA1 for Ovarian Cancer

Click here to visit the biomarker database for more information on OVA1.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.

Announcement 01/30/2017

Please visit http://www.compass. fhcrc.org/meeting/reg_edrn/edrnsc.aspx for information and to register for the 31st EDRN Steering Committee Meeting in Tempe, AZ, from March 6-9, 2017.

Announcement